Caribou Biosciences, Inc. (CRBU) Quick Ratio
- Quick ratio · latest quarter: Value 6.26×; Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | 6.26× | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. $112.52M ÷ $17.97M ≈ 6.26× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | 112.52M USD | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current · Debt Securities, Available-for-sale, Current · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 17.97M USD | Liabilities, Current |
| Cash and equivalents | 26.19M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 86.12M USD | Marketable Securities, Current · Debt Securities, Available-for-sale, Current |
| Customer receivables | 203.00K USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $112.52M | $17.97M | $26.19M | $86.12M | $203.00K | (m) | 6.26× |
| 2026-03-31 | $117.85M | $19.67M | $12.06M | $105.57M | $227.00K | (m) | 5.99× |
| 2025-12-31 | $139.41M | $25.41M | $12.36M | $126.98M | $69.00K | (m) | 5.49× |
| 2025-09-30 | $147.50M | $28.06M | $11.14M | $136.12M | $242.00K | (m) | 5.26× |
| 2025-06-30 | $184.02M | $28.89M | $25.20M | $158.75M | $71.00K | (m) | 6.37× |
| 2025-03-31 | $208.55M | $28.49M | $29.42M | $179.05M | $88.00K | (m) | 7.32× |
| 2024-12-31 | $209.80M | $30.65M | $16.29M | $193.24M | $265.00K | (m) | 6.84× |
| 2024-09-30 | $228.36M | $32.16M | $31.97M | $196.21M | $184.00K | (m) | 7.10× |
| 2024-06-30 | $261.86M | $30.94M | $37.87M | $223.78M | $215.00K | (m) | 8.46× |
| 2024-03-31 | $294.90M | $29.02M | $49.40M | $244.59M | $917.00K | (m) | 10.16× |
| 2023-12-31 | $328.98M | $28.30M | $51.16M | $277.67M | $148.00K | (m) | 11.62× |
| 2023-09-30 | $339.62M | $24.57M | $104.06M | $234.43M | $1.13M | (m) | 13.82× |
| 2023-06-30 | $260.00M | $34.38M | $66.19M | $193.04M | $766.00K | (m) | 7.56× |
| 2023-03-31 | $230.07M | $27.10M | $52.74M | $175.79M | $1.53M | (m) | 8.49× |
| 2022-12-31 | $247.87M | $28.13M | $58.34M | $189.32M | $202.00K | (m) | 8.81× |
| 2022-09-30 | $293.77M | $28.81M | $82.08M | $211.28M | $397.00K | (m) | 10.20× |
| 2022-06-30 | $340.45M | $28.86M | $112.15M | $227.78M | $524.00K | (m) | 11.80× |
| 2022-03-31 | $354.11M | $26.67M | $147.63M | $206.10M | $374.00K | (m) | 13.28× |
| 2021-12-31 | $376.99M | $25.83M | $240.42M | $135.41M | $1.15M | (m) | 14.60× |
| 2021-09-30 | (m) | $26.16M | $435.31M | (m) | $578.00K | (m) | (m) |
| 2021-06-30 | (m) | $26.01M | $129.52M | (m) | $2.00K | (m) | (m) |
| 2021-03-31 | (m) | (m) | $145.92M | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | $12.39M | $15.95M | (m) | $150.00K | (m) | (m) |
| 2020-09-30 | (m) | (m) | $24.55M | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | $33.13M | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | (m) | $41.07M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |